Effect of levamisole treatment on immunological parameters and the early course of cervical cancer.
Immunological parameters and the early course of the disease have been studied in 153 cases of cervical cancer. Fifty-two patients were given levamisole as an adjuvant. At the end of a 9-month observation period, immunological parameters of apparently clinically tumor-free patients were compared for two groups: traditional treatment versus traditional treatment plus levamisole. Low IgM concentrations and reduced cutaneous reactivity to phytohemagglutinin were found in both groups, but reduction of the two parameters was slighter in the levamisole group. With reference to pertinent literature and the authors' results, the possible effects of levamisole are discussed, as well as possibilities and place of the drug in the therapy of cervical cancer.
D002272:Carcinoembryonic Antigen / Q000032:analysis; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007978:Levamisole / Q000627:therapeutic use*; D008875:Middle Aged; D010835:Phytohemagglutinins; D012882:Skin Tests; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000276:immunology; D000511:alpha-Macroglobulins / Q000032:analysis
D002272:Carcinoembryonic Antigen; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D010835:Phytohemagglutinins; D000511:alpha-Macroglobulins; D007978:Levamisole